• 1
    Gorman NT, Halliwell REW. Mechanisms of immunological injury in hypersensitivity reactions. In: HalliwellREW, GormanNT, eds. Veterinary Clinical Immunology. Philadelphia : WB Saunders, 1989; 212231.
  • 2
    Jerne NK. Towards a network theory ofthe immune system. Ann lmmunol (Inst Pasteur) 1974; 125C:373389.
  • 3
    Meischer PA, Beris P. Immunosuppressive therapy in the treatment of autoimmune diseases. Springer Semin lmmunopathol 1984; 7:6990.
  • 4
    Bore Y. From nonspecific to specific immunosuppression: facts and speculation. Springer Semin lmmunpathol 1984; 7: 1924.
  • 5
    Klein MK, Dow SW, Rosychuk RAW. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982–1987). J Am Vet Med Assoc 1989; 195:246250.
  • 6
    Abdou NI, Wall H., Lindsley HB, et al. Network theory ofautoimmunity: In vitrosuppression ofserum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest 1981; 67:12971304.
  • 7
    Wasserman NH, Penn AS, Freimuth PI, et al. Anti-idiotypic route to anti-acetylcholine receptor antibodies and experimental myasthenia gravis. Proc Natl Acad Sci 1982; 79:48104814.
  • 8
    Gorman NT, Werner LL. Immune-mediated diseases of the dog and cat. I. Basic concepts and the systemic immune-mediated diseases. Br Vet J 1986; 142: 395402.
  • 9
    Dwyer DS, Bradley RJ, Urquhart CK, et al. Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature 1983; 301:611614.
  • 10
    Chastain CB, Young DW, Kemppainen RJ. Anti-triiodothyronine antibodies associated with hypothyroidism and lymphocytic thyroiditis in a dog. J Am Vet Med Assoc 1989; 194:531534.
  • 11
    Beale KM, Halliwell REW, Chen CL. Prevalence of antithyroglobulin antibodies detected by enzyme-linked immunosorbent assay of canine serum. J Am Vet Med Assoc 1990; 745748.
  • 12
    Plotz PH. Autoantibodies are anti-idiotype antibodies to antiviral antibodies. Lancet 1983; 824826.
  • 13
    Christiansen ML, Pachman LM, Maryjowski MC, et al. Antibody to coxsackie B virus: increased incidence in children with recently diagnosed dermatomyositis. Arthrit Rheum 1983; 26:24.
  • 14
    Nelson AM, Conn DL. Glucocorticoids in rheumatic disease. Mayo Clin Proc 1980; 55:758769.
  • 15
    Nara PL, Krakowka S., Powers TE. Effects of prednisolone on the development of immune responses to canine distemper virus in Beagle pups. Am J Vet Res 1979; 40: 17421747.
  • 16
    Beale KM. Azathioprine for treatment of immune-mediated diseases of dogs and cats. J Am Vet Med Assoc 1988; 192:13161318.
  • 17
    Stanton M., Legendre AM. Effects of cyclophosphamide in dogs and cats. J Am Vet Med Assoc 1986; 188: 13191322.
  • 18
    Jenkins TS, Black KS, Hewitt CW. Treatment of autoimmune hemolytic anemia in the dog. Canine Pract 1986; 13:3945.
  • 19
    White JV. Cyclosporine: Prototype of a T-cell selective immunosuppressant. J Am Vet Med Assoc 1986; 189:566570.
  • 20
    Klausner JS, Poffenbarger EM, Matus R. Therapeutic Hemapheresis. In: KirkRW, ed. Current Veterinary Therapy. Philadelphia : WB Saunders, 1986; 110113.
  • 21
    Kennedy MS, Domen RE. Therapeutic apheresis: applications and future directions. Vox Sang 1983; 45:261277.
  • 22
    Calabrese LH, Clough JD, Krakauer RS, et al. Plasmapheresis therapy of immunologic disease: report of nine cases and review of the literature. Cleveland Clin Quart 1980; 475372.
  • 23
    Matus RE, Gordon BR, Leifer CE, et al. Plasmapheresis in five dogs with systemic immune-mediated disease. J Am Vet Med ASSOC 1985; 1871:595599.
  • 24
    Bartges JW, Klausner JS, Bostwick EF, et al. Clinical remission following plasma-pheresis and corticosteroid treatment in a dog with acquired myasthenia gravis. J Am Vet Med Assoc 1990: 196:12761278.
  • 25
    Matus RE, Schrader LA, Leifer CE, et al. Plasmapheresis as adjuvant therapy for autoimmune hemolytic anemia in two dogs. J Am Vet Med Assoc 1985; 186:691693.
  • 26
    Talal N. The goals of immunologic intervention in autoimmune disease. J Autoimmunity 1989; 2:257264.
  • 27
    McDevitt HO, Perry R., Steinman LA. Monoclonal anti-la antibody therapy in animal models of autoimmune disease. Ciba Found Symp 1987; 129:184193.
  • 28
    Murphy S., LoBuglio AF. Drug therapy of autoimmune hemolytic anemia. Semin Hematol 1976; 13:323334.
  • 29
    McGuire WA, Yang HH, Bruno E., et al. Treatment of antibodymediated pure red-cell aplasia with high-dose intravenous gamma globuloin. N Eng J Med 1987; 317:10041007.
  • 30
    Bussel JB, Cunningham-Rundles C. Intravenous gammaglobulin treatment of humoral immunodeficiency disease and autoimmune hematologic disease. Pharmacol Physicians 1984; 18:17.
  • 31
    Bussel JB. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura. J Allergy Clin Immunol 1989; 84566578.
  • 32
    Talal N. New therapeutic approaches to autoimmune disease. Springer Semin Immunopathol 1986; 9:105116.
  • 33
    Ahn YS, Hamngton WJ, Mylvaganam R., et al. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 1985; 102:298302.
  • 34
    West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1988; 108:703706.
  • 35
    Marino C., Cook P. Danazol for lupus thrombocytopenia. Arch Intern Med 1985; 145:22512252.
  • 36
    Bloom JC, Meunier LD, Thiem PA, et al. Use ofdanazol for treatment of corticosteroid-resistant immune-mediated thrombocytopenia in a dog. J Am Vet Med Assoc 1989; 194:7678.
  • 37
    Schreiber AD, Chien P., Towaski A., et al. Effect of danazol therapy on the expression of the human monocyte Fc (IgG) receptor. Blood 1984; 64:273.
  • 38
    Clarkson SB. Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with ant-Fegamma-receptor antibody. N Engl J Med 1986; 314:12361239.
  • 39
    Klein J. The organs of the immune system. In: KleinJ., ed. The Science of Self-Nonself Discrimination. New York John Wiley and Sons, 1982; 5491.
  • 40
    Feldman BF, Handagama P., Lubberink AAME. Splenectomy as adjunctive therapy for immune-mediated thrombocytopenia and hemolytic anemia in the dog. J Am Vet Med Assoc 1985; 187:617619.
  • 41
    Jans HE, Armstrong J., Price GS. Therapy of immune mediated thrombocytopenia: A retrospective study of I5 dogs. J Vet Intern Med 1990; 4: 47.
  • 42
    Ahn YS, Hamngton WJ, Byrnes JJ, et al. Treatment of autoimmune hemolytic anemia with vinca-loaded platelets. J Am Med Assoc 1983; 249:21892194.
  • 43
    Hopkins SJ, Humphreys M., Jayson IV. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-I. Clin Exp Immunol 1988; 72: 422427.
  • 44
    Saxne T., Palladino MA, Heingard D., et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor F6b in rheumatoid arthritis synovial fluid and serum. Arthrit Rheum 1988; 31:10411045.
  • 45
    Revel M., Schattner A. Interferons: cytokines in autoimmunity. Ciba Found Symp 1987; 129:223227.
  • 46
    Schattner A. Review: interferons and autoimmunity. Am J Med Sci 1988; 295532544.
  • 47
    Kupiec-Weglinski JW, Diamantstein T., Tilney NL, et al. Therapy with monoclonal antibody to interleukin-2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci 1986; 83:26242627.
  • 48
    Kelley VE, Gaulton GN, Hattori M., et al. Anti-interleukin-2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 1988; 140:5961.
  • 49
    Bacha P., Williams DP, Waters C., et al. Interleukin-2 receptor targeted cytotoxicity. Interleukin-2 receptor mediated action of a diphtheria toxin related interleukin-2 fusion protein. J Exp Med 1988; 167: 612622.
  • 50
    Wofsky D. Strategies for treating autoimmune disease with monoclonal antibodies. West J Med 1985; 1435:304809.
  • 51
    Hanson B. Leukotrienes: biology and role in disease. J Vet Intern Med 1989; 35972.
  • 52
    Boothe DM. Prostaglandins: physiology and clinical implications. Comp Cont Educ 1984; 6:10101021.
  • 53
    Dinarello CA. Interleukin-I and the pathogenesis of the acutephase response. N Engl J Med 1984; 311:14131418.
  • 54
    Homsy J., Morrow WJW, Levy JA. Nutrition and autoimmunity: A review. Clin Exp Immunol 1986; 65:473488.
  • 55
    Robinson DR, Hirai A., Steinberg, et al. Alleviation of murine autoimmune disease by dietary marine lipids. Adv Prostagland Thromboxane Leukotriene Res 1987; 17:850853.
  • 56
    Kremer J., Bigasuoette J., Michalek AV, et al. Effects of manipulation ofdietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1985; i:84.
  • 57
    Ogilvie GK, Felsburg PJ, Hams CW. Short-term effects of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol 1988; 18:119127.